Literature DB >> 24327695

Personalized therapy for acute myeloid leukemia.

Christopher S Hourigan1, Judith E Karp.   

Abstract

Patient-specific ex vivo drug sensitivity and resistance screening can identify rational drug candidates for the testing of personalized targeted therapy. An iterative approach of genomic and drug susceptibility characterization at sequential time points during clinical trials of targeted therapy in acute myeloid leukemia may be useful both for characterizing mechanisms of resistance and clonal evolution and also for identification of novel therapeutic targets and drug combinations. ©2013 AACR.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24327695      PMCID： PMC3880545          DOI： 10.1158/2159-8290.CD-13-0832

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  11 in total

1.  A clinically relevant population of leukemic CD34(+)CD38(-) cells in acute myeloid leukemia.

Authors:  Jonathan M Gerber; B Douglas Smith; Brownhilda Ngwang; Hao Zhang; Milada S Vala; Laura Morsberger; Steven Galkin; Michael I Collector; Brandy Perkins; Mark J Levis; Constance A Griffin; Saul J Sharkis; Michael J Borowitz; Judith E Karp; Richard J Jones
Journal:  Blood       Date:  2012-01-19       Impact factor: 22.113

2.  The origin and evolution of mutations in acute myeloid leukemia.

Authors:  John S Welch; Timothy J Ley; Daniel C Link; Christopher A Miller; David E Larson; Daniel C Koboldt; Lukas D Wartman; Tamara L Lamprecht; Fulu Liu; Jun Xia; Cyriac Kandoth; Robert S Fulton; Michael D McLellan; David J Dooling; John W Wallis; Ken Chen; Christopher C Harris; Heather K Schmidt; Joelle M Kalicki-Veizer; Charles Lu; Qunyuan Zhang; Ling Lin; Michelle D O'Laughlin; Joshua F McMichael; Kim D Delehaunty; Lucinda A Fulton; Vincent J Magrini; Sean D McGrath; Ryan T Demeter; Tammi L Vickery; Jasreet Hundal; Lisa L Cook; Gary W Swift; Jerry P Reed; Patricia A Alldredge; Todd N Wylie; Jason R Walker; Mark A Watson; Sharon E Heath; William D Shannon; Nobish Varghese; Rakesh Nagarajan; Jacqueline E Payton; Jack D Baty; Shashikant Kulkarni; Jeffery M Klco; Michael H Tomasson; Peter Westervelt; Matthew J Walter; Timothy A Graubert; John F DiPersio; Li Ding; Elaine R Mardis; Richard K Wilson
Journal:  Cell       Date:  2012-07-20       Impact factor: 41.582

3.  Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia.

Authors:  Tea Pemovska; Mika Kontro; Bhagwan Yadav; Henrik Edgren; Samuli Eldfors; Agnieszka Szwajda; Henrikki Almusa; Maxim M Bespalov; Pekka Ellonen; Erkki Elonen; Bjørn T Gjertsen; Riikka Karjalainen; Evgeny Kulesskiy; Sonja Lagström; Anna Lehto; Maija Lepistö; Tuija Lundán; Muntasir Mamun Majumder; Jesus M Lopez Marti; Pirkko Mattila; Astrid Murumägi; Satu Mustjoki; Aino Palva; Alun Parsons; Tero Pirttinen; Maria E Rämet; Minna Suvela; Laura Turunen; Imre Västrik; Maija Wolf; Jonathan Knowles; Tero Aittokallio; Caroline A Heckman; Kimmo Porkka; Olli Kallioniemi; Krister Wennerberg
Journal:  Cancer Discov       Date:  2013-09-20       Impact factor: 39.397

4.  Phase I study of quizartinib administered daily to patients with relapsed or refractory acute myeloid leukemia irrespective of FMS-like tyrosine kinase 3-internal tandem duplication status.

Authors:  Jorge E Cortes; Hagop Kantarjian; James M Foran; Darejan Ghirdaladze; Mamia Zodelava; Gautam Borthakur; Guy Gammon; Denise Trone; Robert C Armstrong; Joyce James; Mark Levis
Journal:  J Clin Oncol       Date:  2013-09-03       Impact factor: 44.544

Review 5.  Minimal residual disease in acute myeloid leukaemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Nat Rev Clin Oncol       Date:  2013-06-25       Impact factor: 66.675

6.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia.

Authors:  Jay P Patel; Mithat Gönen; Maria E Figueroa; Hugo Fernandez; Zhuoxin Sun; Janis Racevskis; Pieter Van Vlierberghe; Igor Dolgalev; Sabrena Thomas; Olga Aminova; Kety Huberman; Janice Cheng; Agnes Viale; Nicholas D Socci; Adriana Heguy; Athena Cherry; Gail Vance; Rodney R Higgins; Rhett P Ketterling; Robert E Gallagher; Mark Litzow; Marcel R M van den Brink; Hillard M Lazarus; Jacob M Rowe; Selina Luger; Adolfo Ferrando; Elisabeth Paietta; Martin S Tallman; Ari Melnick; Omar Abdel-Wahab; Ross L Levine
Journal:  N Engl J Med       Date:  2012-03-14       Impact factor: 91.245

7.  New considerations in the design of clinical trials for the treatment of acute leukemia.

Authors:  Christopher S Hourigan; Judith E Karp
Journal:  Clin Investig (Lond)       Date:  2011-04-01

8.  Multidrug resistance in relapsed acute myeloid leukemia: evidence of biological heterogeneity.

Authors:  Chirayu Patel; Leif Stenke; Sudhir Varma; Marita Lagergren Lindberg; Magnus Björkholm; Jan Sjöberg; Kristina Viktorsson; Rolf Lewensohn; Ola Landgren; Michael M Gottesman; Jean-Pierre Gillet
Journal:  Cancer       Date:  2013-05-14       Impact factor: 6.860

9.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia.

Authors:  Timothy J Ley; Christopher Miller; Li Ding; Benjamin J Raphael; Andrew J Mungall; A Gordon Robertson; Katherine Hoadley; Timothy J Triche; Peter W Laird; Jack D Baty; Lucinda L Fulton; Robert Fulton; Sharon E Heath; Joelle Kalicki-Veizer; Cyriac Kandoth; Jeffery M Klco; Daniel C Koboldt; Krishna-Latha Kanchi; Shashikant Kulkarni; Tamara L Lamprecht; David E Larson; Ling Lin; Charles Lu; Michael D McLellan; Joshua F McMichael; Jacqueline Payton; Heather Schmidt; David H Spencer; Michael H Tomasson; John W Wallis; Lukas D Wartman; Mark A Watson; John Welch; Michael C Wendl; Adrian Ally; Miruna Balasundaram; Inanc Birol; Yaron Butterfield; Readman Chiu; Andy Chu; Eric Chuah; Hye-Jung Chun; Richard Corbett; Noreen Dhalla; Ranabir Guin; An He; Carrie Hirst; Martin Hirst; Robert A Holt; Steven Jones; Aly Karsan; Darlene Lee; Haiyan I Li; Marco A Marra; Michael Mayo; Richard A Moore; Karen Mungall; Jeremy Parker; Erin Pleasance; Patrick Plettner; Jacquie Schein; Dominik Stoll; Lucas Swanson; Angela Tam; Nina Thiessen; Richard Varhol; Natasja Wye; Yongjun Zhao; Stacey Gabriel; Gad Getz; Carrie Sougnez; Lihua Zou; Mark D M Leiserson; Fabio Vandin; Hsin-Ta Wu; Frederick Applebaum; Stephen B Baylin; Rehan Akbani; Bradley M Broom; Ken Chen; Thomas C Motter; Khanh Nguyen; John N Weinstein; Nianziang Zhang; Martin L Ferguson; Christopher Adams; Aaron Black; Jay Bowen; Julie Gastier-Foster; Thomas Grossman; Tara Lichtenberg; Lisa Wise; Tanja Davidsen; John A Demchok; Kenna R Mills Shaw; Margi Sheth; Heidi J Sofia; Liming Yang; James R Downing; Greg Eley
Journal:  N Engl J Med       Date:  2013-05-01       Impact factor: 91.245

10.  Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing.

Authors:  Li Ding; Timothy J Ley; David E Larson; Christopher A Miller; Daniel C Koboldt; John S Welch; Julie K Ritchey; Margaret A Young; Tamara Lamprecht; Michael D McLellan; Joshua F McMichael; John W Wallis; Charles Lu; Dong Shen; Christopher C Harris; David J Dooling; Robert S Fulton; Lucinda L Fulton; Ken Chen; Heather Schmidt; Joelle Kalicki-Veizer; Vincent J Magrini; Lisa Cook; Sean D McGrath; Tammi L Vickery; Michael C Wendl; Sharon Heath; Mark A Watson; Daniel C Link; Michael H Tomasson; William D Shannon; Jacqueline E Payton; Shashikant Kulkarni; Peter Westervelt; Matthew J Walter; Timothy A Graubert; Elaine R Mardis; Richard K Wilson; John F DiPersio
Journal:  Nature       Date:  2012-01-11       Impact factor: 49.962
View more
  5 in total

1.  Precision medicine for acute myeloid leukemia.

Authors:  Catherine Lai; Judith E Karp; Christopher S Hourigan
Journal:  Expert Rev Hematol       Date:  2015-10-30       Impact factor: 2.929

2.  Modelling acute myeloid leukemia (AML): What's new? A transition from the classical to the modern.

Authors:  Annachiara Dozzo; Aoife Galvin; Jae-Won Shin; Santo Scalia; Caitriona M O'Driscoll; Katie B Ryan
Journal:  Drug Deliv Transl Res       Date:  2022-08-05       Impact factor: 5.671

3.  Current Approaches in the Treatment of Relapsed and Refractory Acute Myeloid Leukemia.

Authors:  Nestor R Ramos; Clifton C Mo; Judith E Karp; Christopher S Hourigan
Journal:  J Clin Med       Date:  2015-04       Impact factor: 4.241

4.  Cytoplasmic proliferating cell nuclear antigen connects glycolysis and cell survival in acute myeloid leukemia.

Authors:  Delphine Ohayon; Alessia De Chiara; Nicolas Chapuis; Céline Candalh; Julie Mocek; Jean-Antoine Ribeil; Lamya Haddaoui; Norbert Ifrah; Olivier Hermine; Frédéric Bouillaud; Philippe Frachet; Didier Bouscary; Véronique Witko-Sarsat
Journal:  Sci Rep       Date:  2016-10-19       Impact factor: 4.379

5.  Interrogation of novel CDK2/9 inhibitor fadraciclib (CYC065) as a potential therapeutic approach for AML.

Authors:  Wittawat Chantkran; Ya-Ching Hsieh; Daniella Zheleva; Sheelagh Frame; Helen Wheadon; Mhairi Copland
Journal:  Cell Death Discov       Date:  2021-06-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.